Mocon (MOCO) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document and Entity Information	'	'
Entity Registrant Name	'MOCON INC	'
Entity Central Index Key	'0000067279	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	5,549,129
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$4,494,316	$2,415,416
Marketable securities, current	451,357	5,495,556
Trade accounts receivable, less allowance for doubtful accounts of $303,656 in 2013 and $303,839 in 2012	11,167,814	10,407,649
Other receivables	240,751	244,081
Inventories	7,002,238	6,344,982
Prepaid income taxes	351,652	279,964
Prepaid expenses, other	1,035,647	799,124
Deferred income taxes	1,280,526	926,081
Total current assets	26,024,301	26,912,853
Marketable securities, noncurrent	'	210,440
Property, plant and equipment, net of accumulated depreciation of $7,516,707 in 2013 and $6,876,028 in 2012	5,738,650	5,350,310
Goodwill	8,901,744	8,729,438
Investment in affiliated company	3,380,000	3,303,750
Intangible assets, net	12,596,514	12,381,614
Other assets	279,360	308,996
Deferred income taxes	137,471	22,370
TOTAL ASSETS	57,058,040	57,219,771
Current liabilities:	'	'
Current maturities of long-term notes payable	2,624,889	2,566,154
Revolving lines of credit	2,550,000	5,327,515
Accounts payable	3,884,483	2,893,225
Compensation and related expenses	3,318,941	3,510,272
Other accrued expenses	862,460	868,199
Accrued product warranties	241,318	240,621
Accrued income taxes	501,320	36,139
Dividends payable	610,404	579,386
Deferred revenue	863,592	472,185
Total current liabilities	15,457,407	16,493,696
Notes payable	2,433,517	3,926,863
Obligations to former employees	77,910	76,161
Deferred income taxes	2,395,361	2,576,396
Accrued income taxes	296,949	265,207
Total noncurrent liabilities	5,203,737	6,844,627
Total liabilities	20,661,144	23,338,323
Stockholders' equity:	'	'
Capital stock - undesignated. Authorized 3,000,000 shares; none issued and outstanding in 2013 and 2012	'	'
Common stock - $0.10 par value. Authorized 22,000,000 shares; issued and outstanding 5,549,129 shares in 2013 and 5,517,966 shares in 2012	554,913	551,797
Additional paid-in capital	4,402,003	3,738,968
Retained earnings	31,415,665	30,217,977
Accumulated other comprehensive loss	24,315	-627,294
Total stockholders' equity	36,396,896	33,881,448
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$57,058,040	$57,219,771

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Trade accounts receivable, allowance for doubtful accounts (in dollars)	$303,656	$303,839
Property, plant and equipment, accumulated depreciation (in dollars)	$7,516,707	$6,876,028
Capital stock, Authorized shares	3,000,000	3,000,000
Capital stock, issued shares	0	0
Capital stock, outstanding shares	0	0
Common stock, par value (in dollars per share)	$0.10	$0.10
Common stock, Authorized shares	22,000,000	22,000,000
Common stock, issued shares	5,549,129	5,517,966
Common stock, outstanding shares	5,549,129	5,517,966

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Sales:	'	'	'	'
Products	$13,400,132	$11,588,804	$40,088,427	$32,516,670
Consulting services	789,741	717,347	2,236,639	2,172,215
Total sales	14,189,873	12,306,151	42,325,066	34,688,885
Cost of sales:	'	'	'	'
Products	5,657,331	5,120,131	17,275,469	14,508,813
Consulting services	473,621	472,801	1,356,904	1,323,752
Total cost of sales	6,130,952	5,592,932	18,632,373	15,832,565
Gross profit	8,058,921	6,713,219	23,692,693	18,856,320
Selling, general and administrative expenses	5,257,664	5,103,957	16,528,574	14,482,256
Research and development expenses	886,289	843,780	3,084,583	2,609,929
Operating income	1,914,968	765,482	4,079,536	1,764,135
Other income (expense), net	-95,308	-25,815	-285,990	116,890
Income before income taxes	1,819,660	739,667	3,793,546	1,881,025
Income tax expense (benefit)	460,999	246,577	766,637	709,422
Net income	$1,358,661	$493,090	$3,026,909	$1,171,603
Net income per common share:	'	'	'	'
Basic (in dollars per share)	$0.24	$0.09	$0.55	$0.21
Diluted (in dollars per share)	$0.24	$0.09	$0.53	$0.21
Weighted average common shares outstanding:	'	'	'	'
Basic (in shares)	5,548,201	5,477,928	5,535,687	5,467,450
Diluted (in shares)	5,684,515	5,683,436	5,673,694	5,695,305
Cash dividends declared per common share (in dollars per share)	$0.11	$0.11	$0.33	$0.32

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	'	'	'	'
Net income	$1,358,661	$493,090	$3,026,909	$1,171,603
Other comprehensive income (loss):	'	'	'	'
Cumulative translation adjustment	1,058,066	675,427	651,609	-727,494
Comprehensive income	$2,416,727	$1,168,517	$3,678,518	$444,109

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income	$3,026,909	$1,171,603
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Stock-based compensation expense	390,269	350,978
Change in fair value of derivative instrument	-8,041	-205,156
Gain on disposition of long-term assets	-44,889	-12,563
Depreciation and amortization	1,795,379	1,217,850
Deferred income taxes	-696,569	-115,378
Excess tax benefit from employee stock plans	-19,670	-57,714
Changes in operating assets and liabilities:	'	'
Trade accounts receivable, net	-589,435	-96,919
Other receivables	47,421	211,569
Inventories	-603,719	795,264
Prepaid income taxes	-66,391	-208,602
Prepaid expenses, other	-231,019	-119,614
Accounts payable	758,978	-181,288
Compensation and related expenses	-227,579	-810,071
Other accrued expenses	-4,666	-69,682
Accrued product warranties	-1,738	-35,166
Accrued income taxes	503,719	-706,124
Deferred revenue	385,608	-734,359
Net cash provided by operating activities	4,414,567	394,628
Cash flows from investing activities:	'	'
Purchases of marketable securities	'	-365,000
Proceeds from maturities of marketable securities	5,254,639	3,704,521
Purchases of property, plant and equipment	-1,308,243	-1,070,682
Proceeds from sale of property and equipment	116,234	171,461
Payment for purchase of Dansensor, net of cash acquired	'	-12,764,429
Cash paid for patents and other intangible assets	-669,154	-207,642
Other	-2,259	3,296
Net cash provided by (used in) investing activities	3,391,217	-10,528,475
Cash flows from financing activities:	'	'
Proceeds from the revolving lines of credit	4,757,484	6,875,000
Payments on the revolving lines of credit	-7,532,789	-2,387,353
Proceeds from term note payable	'	3,500,000
Payments on notes payable and seller financed note payable	-1,453,660	-2,559,102
Proceeds from the exercise of stock options	256,212	350,088
Excess tax benefit from employee stock plans	19,670	57,714
Dividends paid	-1,798,208	-1,693,790
Net cash provided by (used in) financing activities	-5,751,291	4,142,557
Effect of exchange rate changes on cash and cash equivalents	24,407	-53,893
Net increase (decrease) in cash and cash equivalents	2,078,900	-6,045,183
Cash and cash equivalents:	'	'
Beginning of period	2,415,416	8,425,846
End of period	4,494,316	2,380,663
Supplemental disclosures of cash flow information:	'	'
Cash paid during the period for income taxes	1,166,483	1,584,839
Cash paid during the period for interest	221,299	87,250
Supplemental schedule of noncash investing and financing activities:	'	'
Dividends accrued	610,404	575,672
Purchases of fixed assets and intangibles in accounts payable	217,344	220,088
Seller financed note payable for the acquisition of Dansensor	'	6,378,800
The Company purchased all of the common shares of Dansensor for $20,081,600 on April 2, 2012. The reconciliation of cash paid and liabilities assumed is as follows:	'	'
Fair value of assets acquired	'	26,938,817
Liabilities assumed	'	-6,857,217
Net acquired assets	'	20,081,600
Seller financed note payable	'	-6,484,413
Cash acquired	'	-832,758
Payment for purchase of Dansensor, net of cash acquired and seller financed note payable	'	$12,764,429

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	0 Months Ended
	Apr. 02, 2012
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS	'
Purchase price for Danensor common shares	$20,081,600

Condensed_Consolidated_Financi

Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2013
Condensed Consolidated Financial Statements	'
Condensed Consolidated Financial Statements	'
	Note 1 — Condensed Consolidated Financial Statements
	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.  These interim unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to fairly present the financial position, results of operations and cash flows for all periods presented.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.
	The results of operations for the three and nine-month periods ended September 30, 2013 are not necessarily indicative of operating results for the full year.  It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, previously filed with the Securities and Exchange Commission.
	MOCON Inc. and its subsidiaries (collectively, the Company), develops, manufactures and markets  measurement, analytical and  monitoring instruments, and provides consulting services for customers in the barrier packaging, food, pharmaceutical, consumer products, industrial hygiene, environmental, air quality monitoring, oil and gas exploration and other industries throughout the world.  The Company’s acquisition of Dansensor A/S (Dansensor) in 2012 expanded the Company’s offerings into the Modified Atmosphere Packaging (MAP) market world-wide.  MAP technology enables food packagers in a variety of food service industries to produce an extended shelf life by altering the gas mixture within the packaged environment, thereby reducing the need for artificial preservatives.
	During the second quarter of fiscal 2012, the Company acquired all of the issued and outstanding shares of Dansensor, a Danish company. Dansensor designs, manufactures, sells, and services quality control and assurance equipment for businesses that utilize modified atmosphere or sealed packaging.  Dansensor also offers a complete range of gas mixers, analyzers, and leak detection equipment and sells its products world-wide. The acquisition significantly expands the Company’s presence in Europe and particularly in MAP technology, a growing world-wide market.  All of the assets and liabilities of Dansensor were recorded in the Condensed Consolidated Balance Sheets at their respective fair values on the date of acquisition.
	During fiscal 2012, the Company increased the number of reporting segments from one to three to reflect the integration of Dansensor’s operations.  These are classified as Permeation Products and Services (“Permeation”), Package Testing Products and Services (“Package Testing”), and Industrial Analyzer Products and Services and Other (“Industrial Analyzers and Other”) for financial reporting purposes.
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of MOCON, Inc. and its wholly-owned subsidiaries (collectively the Company).  All intercompany balances and transactions have been eliminated in consolidation.
	Recently Adopted Accounting Pronouncements
	Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income
	On January 1, 2013, the Company adopted the FASB issued disclosure requirements with respect to changes in accumulated other comprehensive income (AOCI). Under this new guidance, companies are required to disclose the amount of income (or loss) reclassified out of AOCI to each respective line item on the statements of income where net income is presented on either the face of the financial statements or within the footnotes. The provisions of the guidance are to be applied prospectively for reporting periods beginning after December 15, 2012. The Company has elected to disclose the reclassification in the notes to the financial statements (see Note 7).

Business_Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2013
Business Acquisition	'
Business Acquisition	'
	Note 2 — Business Acquisition
	On April 2, 2012, the Company acquired all of the issued and outstanding shares of Dansensor pursuant to a Share Purchase Agreement (SPA).  Under the terms of the SPA, the Company acquired Dansensor for approximately $19.2 million, net of cash acquired.  Approximately $13.6 million of the purchase price was paid in cash at closing and the remainder of the purchase price was paid through the issuance of the Seller Note as is more fully described in Note 10.
	The supplemental unaudited pro forma net sales and net income of the combined entity, including U.S. GAAP conversion adjustments, had the acquisition been completed as of the earliest period presented are as follows:
		Net Sales			Net Income		Basic
							Earnings
							per Share
	Supplemental pro forma combined results of operations:
	Nine-month period ended September 30, 2012	$	43,748,390		$	1,185,140	$	0.22
	Material items included in the supplemental unaudited pro forma disclosures above are as follows:
		Nine Months
		Ended
		September 30,
		2012
	Amortization of intangibles	$	278,338
	Interest expense	106,237
	Income tax effect of adjustments	(115,373		)
		$	269,202
	The Company recorded approximately $790,000 in acquisition related costs during the nine months ended September 30, 2012 which are recorded as selling general and administrative expense in the Condensed Consolidated Statement of Operations as of September 30, 2012.
	These pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The pro forma consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventories	'
Inventories	'
	Note 3 — Inventories
	Inventories consist of the following:
		September 30,		December 31,
		2013		2012
	Finished products	$	1,460,625	$	1,554,203
	Work-in-process	1,840,414		1,599,761
	Raw materials	3,701,199		3,191,018
		$	7,002,238	$	6,344,982

Net_Income_Per_Common_Share

Net Income Per Common Share	9 Months Ended
	Sep. 30, 2013
Net Income Per Common Share	'
Net Income Per Common Share	'
	Note 4 — Net Income Per Common Share
	Basic net income per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.  Diluted net income per common share is computed using the treasury stock method to compute the weighted average common stock outstanding assuming the conversion of potential dilutive common shares.
	The following table presents a reconciliation of the denominators used in the computation of net income per common share — basic, and net income per common share — diluted, for the three and nine-month periods ended September 30, 2013 and 2012:
		Three Months Ended		Nine Months Ended
		September 30,		September 30,
		2013	2012	2013	2012
	Weighted shares of common stock outstanding — basic	5,548,201	5,477,928	5,535,687	5,467,450
	Dilutive impact of share-based awards	136,314	205,508	138,007	227,855
	Weighted shares of common stock outstanding — diluted	5,684,515	5,683,436	5,673,694	5,695,305
	Outstanding stock options totaling 255,650 for the three-month and nine-month periods ended September 30, 2013, and 126,700 for the three and nine-month period ended September 30, 2012, were excluded from the net income per common share calculation because the shares would be anti-dilutive.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets	'
Goodwill and Intangible Assets	'
	Note 5 — Goodwill and Intangible Assets
	The changes in the carrying amount of goodwill for the nine-month period ended September 30, 2013 are as follows:
		Package					Industrial
		Testing		Permeation			Analyzers & Other		Total
	Balance as of December 31, 2012	$	5,940,437	$	2,179,071		$	609,930	$	8,729,438
	Foreign currency translation	128,963		43,343			—		172,306
	Balance as of September 30, 2013	$	6,069,400	$	2,222,414		$	609,930	$	8,901,744
	The Company tests goodwill for impairment annually at the reporting unit level, or when events or changes in circumstances indicate the carrying value of the goodwill might exceed its current fair value.  The Company will perform its annual impairment test for goodwill in the fourth quarter.
	Other intangible assets (all of which are being amortized except projects in process) are as follows:
		As of September 30, 2013
		Cost		Accumulated			Net		Estimated
				Amortization					Useful Lives
	Patents	$	1,525,371	$	(373,292	)	$	1,152,079	10 to 17 years
	Trademarks and trade names	4,388,035		(771,765		)	3,616,270		5 to 20 years
	Developed technology	7,596,470		(1,266,078		)	6,330,392		9 years
	Customer relationships	888,370		(148,062		)	740,308		9 years
	Other intangibles	782,718		(25,253		)	757,465		7 years
		$	15,180,964	$	(2,584,450	)	$	12,596,514
		As of December 31, 2012
		Cost		Accumulated			Net		Estimated
				Amortization					Useful Lives
	Patents	$	1,485,164	$	(428,409	)	$	1,056,755	10 to 17 years
	Trademarks and trade names	4,295,181		(608,861		)	3,686,320		5 to 20 years
	Developed technology	7,424,680		(618,723		)	6,805,957		9 years
	Customer relationships	868,280		(72,357		)	795,923		9 years
	Other intangibles	125,118		(88,459		)	36,659		3.75 years
		$	14,198,423	$	(1,816,809	)	$	12,381,614
	Total amortization expense for the three-month periods ended September 30, 2013 and 2012 was $307,176 and $291,375, respectively and $889,480 and $604,025, respectively, for the nine-month periods ended September 30, 2013 and 2012.  Projects in process are not amortized until the patent or trademark is granted by the regulatory agency or the asset is ready for use.  Estimated amortization expense for the remainder of 2013 and each of the four succeeding fiscal years and thereafter based on the intangible assets as of September 30, 2013 is as follows:
		Estimated
		Expense
	2013	$	347,616
	2014	1,258,089
	2015	1,253,436
	2016	1,236,837
	2017	1,204,513
	2018 and thereafter	6,102,284

Marketable_Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2013
Marketable Securities	'
Marketable Securities	'
	Note 6 — Marketable Securities
	Marketable securities at September 30, 2013 consisted of municipal bonds and certificates of deposits, and are classified as held-to-maturity due to our ability and intent to hold these securities until maturity or the call date as the case may be.  Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts.  A decline in the market value of any held-to-maturity security below the amortized cost basis that is deemed other than temporary is charged to income, resulting in the establishment of a new cost basis for the security.  There was no other than temporary impairment during the nine-month periods ended September 30, 2013 and 2012; therefore, no adjustment to the amortized cost basis was made.  Currently, all of the Company’s marketable securities mature within three months.
	The fair value of the marketable securities above was determined using Level 2 inputs.  There were no gross realized gains or losses for the three and nine-month periods ended September 30, 2013 and 2012.
	The amortized cost and fair value for held-to-maturity securities by major security type at September 30, 2013 and December 31, 2012 were as follows:
		September 30, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding		Holding
				Gains		Losses
	Certificates of deposit	$	245,000	$	118	$	—		$	245,118
	Municipal bonds	206,357		1,053		—			207,410
		$	451,357	$	1,171	$	—		$	452,528
		December 31, 2012
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding		Holding
				Gains		Losses
	Certificates of deposit	$	2,802,993	$	8,684	$	—		$	2,811,677
	Municipal bonds	2,903,003		5,057		(30		)	2,908,030
		$	5,705,996	$	13,741	$	(30	)	$	5,719,707

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss)	'
Accumulated Other Comprehensive Income (Loss)	'
	Note 7 — Accumulated Other Comprehensive Income (Loss)
	Adjustments to accumulated other comprehensive income (loss) consist of the following:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Beginning balance	$	(1,033,751	)	$	(1,992,952	)	$	(627,294	)	$	(590,031	)
	Foreign currency translation adjustments	1,058,066			675,427			651,609			(727,494		)
	Amounts reclassified to earnings	—			—			—			—
	Accumulated other comprehensive income (loss)	$	24,315		$	(1,317,525	)	$	24,315		$	(1,317,525	)

Investment_in_Affiliated_Compa

Investment in Affiliated Company	9 Months Ended
	Sep. 30, 2013
Investment in Affiliated Company	'
Investment in Affiliated Company	'
	Note 8 — Investment in Affiliated Company
	In January 2010, the Company acquired a minority equity ownership interest in Luxcel Biosciences Limited (Luxcel) based in Cork, Ireland.  The investment of €2.5 million (approximately $3.6 million) amounted to a 16.9% equity interest in Luxcel.  The Company has evaluated the cost versus equity method of accounting for its investment in Luxcel and determined that it does not have the ability to exercise significant influence over the operating and financial policies of Luxcel and, therefore, accounts for its investment on a cost basis.  The investment in Luxcel is carried on our Condensed Consolidated Balance Sheets at the original purchase price, adjusted for currency fluctuations.  The Company believes that it is not feasible to readily estimate the fair value of its investment in Luxcel.  Information related to future cash flows of Luxcel is not readily available as the entity is a start-up research and development company and future cash flows are highly dependent on their ability to obtain additional funding, gain acceptance of its products in the marketplace, and obtain regulatory approvals.
	During the three months ended September 30, 2013, the Company paid $200,000 for two license and distribution agreements with Luxcel which grants the Company access to proprietary technology on an exclusive basis for a period of four years.  The agreements also provide for contracted research and development services to be performed by Luxcel.  The terms of the service agreement include upfront payments for each work order placed by the Company of which amounts paid are refundable if the work order is cancelled, excluding amounts incurred for work completed up to the cancellation date.  Total commitments for such work orders total $300,000 as of September 30, 2013, including $100,000 paid during the three months ended on that date.

Warranty

Warranty	9 Months Ended
	Sep. 30, 2013
Warranty	'
Warranty	'
	Note 9 — Warranty
	The Company provides a warranty for most of its products.  Warranties are for periods ranging from ninety days to one year, and cover parts and labor for non-maintenance repairs, at our locations. Operator abuse, improper use, alteration, damage resulting from accident, or failure to follow manufacturer’s directions are excluded from warranty coverage.
	Warranty expense is accrued at the time of sale based on historical claims experience.  Warranty reserves are also accrued for special rework campaigns for known major product modifications.  The Company also offers extended warranty service contracts for select products when the factory warranty period expires.
	Warranty provisions and claims for the three and nine-month periods ended September 30, 2013 and 2012 were as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Beginning balance	$	240,550		$	250,910		$	240,621		$	205,506
	Acquired provision — Dansensor acquisition	—			—			—			85,413
	Warranty provisions	134,327			135,779			300,827			292,657
	Warranty claims	(133,559		)	(128,749		)	(300,130		)	(325,636		)
	Ending balance	$	241,318		$	257,940		$	241,318		$	257,940

Debt

Debt	9 Months Ended
	Sep. 30, 2013
Debt	'
Debt	'
	Note 10 — Debt
	Long-term notes payable consist of the following:
		September 30,		December 31,
		2013		2012
	Note payable to bank, with interest at 3.46%, payable in monthly principal installments of $72,917 plus interest through March 28, 2016, collateralized by all the assets of the Company except the Dansensor stock.	$	2,260,411	$	2,916,664
	Seller financed note payable (Seller Note), with interest at 3.46%, payable in semi-annual payments of principal and interest totaling $891,000 beginning October 2, 2012 through April 2, 2015, collateralized by 65% of the outstanding stock of Dansensor.	2,747,445		3,517,067
	Capital leases	50,550		59,286
	Total long-term notes payable	$	5,058,406	$	6,493,017
	Less current portion of long-term notes payable	2,624,889		2,566,154
	Total long-term notes payable	$	2,433,517	$	3,926,863
	The Company has a $5.0 million secured revolving line of credit with a maturity date of March 28, 2016.  Interest is charged monthly at one-month LIBOR plus 1.75 basis points which totaled 2.00% at September 30, 2013 and December 31, 2012.  The line of credit is secured by the assets of the Company with the exception of the Dansensor stock.  The Company had $2,550,000 and $4,675,000 outstanding on the line of credit at September 30, 2013 and December 31, 2012, respectively.  Additionally, Dansensor has a DKK 10,000,000 (approximately $1.7 million) available line of credit of which no amounts were outstanding as of September 30, 2013 and $652,000 was outstanding at December 31, 2012.  Outstanding borrowings are charged interest at 4.35% per year.
	The Company is subject to various financial and restrictive covenants in the bank Credit Agreement, including maintaining certain financial ratios and limits on incurring additional indebtedness, making capital and lease expenditures and making share repurchases.  As of September 30, 2013, the Company was in compliance with these various covenants.
	The carrying value of the Seller Note is adjusted for foreign currency translation at each reporting period and the change in value is included in other income (expense) in the Condensed Consolidated Statements of Operations.
	As of September 30, 2013, the future minimum principal payments of the long-term notes payable for the remainder of 2013 and each of the four succeeding fiscal years and thereafter are as follows:
	2013	$	1,087,860
	2014	2,666,060
	2015	995,453
	2016	306,119
	2017	2,914
	Total	$	5,058,406

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes	'
Income Taxes	'
	Note 11 — Income Taxes
	Our provision for income tax expense was 25% and 33% of income before income taxes for the third quarters ended September 30, 2013 and 2012, respectively.  The rate in the third quarter 2013 was lower than the statutory rate due primarily to certain discrete adjustments recorded during the quarter.
	The rate in 2012 did not include a benefit for the research credit because Congress had not yet extended the credit for that year at the time.
	For the nine-month period ended September 30, 2013, our income tax expense was 20% of income before income taxes compared to 38% for the same period of 2012. The rate for the first nine months of 2013 was positively impacted by tax law changes related to recently enacted legislation which lowered the corporate income tax rates in Denmark. In addition, the domestic tax law change related to research and development credits which was effective in the first quarter 2013 also positively affected the current year rate. The 2012 provision was higher than normal due primarily to the non-deductibility of certain expenses incurred in relation to the acquisition of Dansensor.
	As of September 30, 2013 and December 31, 2012, the liability for gross unrecognized tax benefits was $297,000 and $265,000, respectively. Changes in gross unrecognized tax benefits during the nine-months ended September 30, 2013 primarily consisted of an increase for tax positions taken in the current year. It is expected that the amount of unrecognized tax benefits for positions which the Company has identified will not materially change in the next twelve months.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation	'
Stock-Based Compensation	'
	Note 12 — Stock-Based Compensation
	As of September 30, 2013, the Company has reserved 273,477 shares of common stock for options and other stock-based incentive awards that are still available for grant under our 2006 stock incentive plan, and 787,475 shares for options that have been granted under either the 2006 stock incentive plan or the 1998 stock option plan but have not yet been exercised. The Company issues new shares of common stock upon exercise of stock options. There were options for an aggregate of 10,000 shares granted in the first nine months of 2013.
	Amounts recognized in the consolidated financial statements related to stock-based compensation are as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Total cost of stock-based compensation	$	129,594		$	116,595		$	390,269		$	350,978
	Amount of income tax benefit recognized in earnings	(14,590		)	(16,897		)	(58,393		)	(62,820		)
	Amount charged against net income	$	115,004		$	99,698		$	331,876		$	288,158
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model (Black-Scholes).  The Company uses historical data to estimate the expected price volatility, expected option life and expected forfeiture rate.  The Company bases its estimate of expected volatility for awards granted on daily historical trading data of its common stock for a period equivalent to the expected term of the award.
	The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option.  The Company estimates the expected term consistent with historical exercise and cancellation activity of its previous share-based grants with a seven year contractual term.  Forfeitures are based on historical experience.  The dividend yield is calculated based upon the dividend payments made during the prior four quarters as a percent of the average stock price for that period.
	A summary of the option activity for the first nine months of 2013 is as follows:
		Number of		Weighted			Weighted		Aggregate
		Shares		Average			Average		Intrinsic
				Exercise			Remaining		Value
				Price per			Contractual
				Share			Term
	Outstanding at December 31, 2012	838,662		$	11.84		3.9		$	2,346,063
	Options granted	10,000		14.16			0.3
	Options cancelled/expired	(12,075	)	14.36
	Options exercised	(49,112	)	10.32
	Outstanding at September 30, 2013	787,475		11.93			3.3		$	1,754,035
	Exercisable at September 30, 2013	626,950		11.32			2.7		$	1,696,384
	The total intrinsic value of options exercised was $10,133 and $44,382 during the three-month periods ended September 30, 2013 and 2012, respectively, and $183,421 and $336,759 during the nine-month periods ended September 30, 2013 and 2012, respectively.
	A summary of the status of our unvested option shares as of September 30, 2013 is as follows:
		Number of		Weighted
		Shares		Average
				Grant Date
				Fair Value
	Unvested at December 31, 2012	209,925		$	4.04
	Options granted	10,000		$	4.45
	Options cancelled	(11,025	)	$	3.83
	Options vested	(48,375	)	$	4.45
	Unvested at September 30, 2013	160,525		$	3.96
	As of September 30, 2013, there was $459,965 of total unrecognized compensation cost related to unvested stock-based compensation granted under our plans.  That cost is expected to be recognized over a weighted-average period of 1.2 years.  The total fair value of option shares vested during the three-month periods ended September 30, 2013 and 2012 was $71,756 and $65,697, respectively, and $215,269 and $197,042 during the nine-month periods ended September 30, 2013 and 2012, respectively.

Derivative_Instrument

Derivative Instrument	9 Months Ended
	Sep. 30, 2013
Derivative Instrument	'
Derivative Instrument	'
	Note 13 — Derivative Instrument
	As of September 30, 2013, the Company has one foreign currency contract outstanding with a notional amount of 15.7 million Danish krone (DKK) or $2.8 million.  The foreign currency contract was purchased to economically hedge the foreign currency fluctuation from the remeasurement of the third party seller financed note payable (Seller Note) which is denominated in DKK (Note 10).  The foreign currency contract has various settlement dates that coincide with the Company’s Seller Note payment schedule.  The term of the foreign currency contract coincides with the maturity of the Seller Note which is April 2, 2015.  The fair value of the contract resulted in an asset of approximately $217,400 at September 30, 2013, as compared to an asset of approximately $209,000 at December 31, 2012.  The increase in the fair value of the contract totaling approximately $103,100 for the three-month period ended September 30, 2013 and the increase of approximately $8,000 for the nine-month period ended September 30, 2013 were recognized in other income (expense) in the Condensed Consolidated Statements of Operations, the current portion of the receivable is recorded in other receivables, and the long-term portion is recorded in other assets as of September 30, 2013.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements	'
Fair Value Measurements	'
	Note 14 — Fair Value Measurements
	The Company determines the fair market value of its derivative contract based on the fair value hierarchy, described below, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels within the fair value hierarchy that may be used to measure fair value:
	Level 1: Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.
	Level 2: Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuation techniques for which all significant assumptions are observable in the market.
	Level 3: Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect our own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models and similar techniques.
	The following table provides information on those assets that are measured at fair value on a recurring basis:
				Fair Value
				Measurements
				at the end of
				the Reporting
				Period Using
	Assets:	Carrying		Significant Other
		value		Observable
				Inputs
				(Level 2)
	September 30, 2013:
	Foreign currency contract	$	217,411	$	217,411
	December 31, 2012:
	Foreign currency contract	$	209,370	$	209,370
	The fair value of the foreign currency contract is determined based on observable market transactions of spot currency rates and forward currency prices. The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, revolving lines of credit and current maturities of notes payable approximate fair value due to their short-term maturity.  The fair value of the long-term debt, measured as Level 2 financial instruments, is estimated based on anticipated interest rates which management believes would currently be available to the Company for similar issues of debt, taking into account the current credit risk of the Company and other market factors. The Company believes the carrying value of the long-term debt approximates fair value.  See Note 6 for additional information on the fair value of the Company’s marketable securities.

Business_Segments

Business Segments	9 Months Ended
	Sep. 30, 2013
Business Segments	'
Business Segments	'
	Note 15 — Business Segments
	As a result of the acquisition of Dansensor during fiscal 2012, the chief operating decision maker (the Company’s President and CEO) restructured the operations of the Company.  In prior reporting periods the Company had three operating segments and one reportable segment, whereas the Company now has four operating segments and three reportable segments, structured by differences in products and services, that are regularly reviewed by the Company’s chief operating decision maker to make decisions about allocating resources and assessing segment performance.  The segment performance is evaluated at segment operating income which is defined as gross profit less selling, general and administrative expenses and research and development expenses.  General corporate expenses, including costs associated with various support functions such as human resources, information technology, finance and accounting, and general and administrative costs, are allocated to the reportable segments primarily on the basis of segment gross margin.  The Company’s four operating segments have been aggregated into three reportable segments based on the authoritative guidance.  The Company aggregated its Other Products and Services operating segment into the Industrial Analyzer Products and Services segment based on minimal business activity and materiality.
	The Permeation segment includes instruments and services that measure the rate at which various gases and vapors permeate through a variety of materials.  The Package Testing segment provides customers with the ability to assess package performance, shelf-life, package improvement, cost reduction, sustainability and product safety using Modified Atmosphere Packaging and other technologies.  The Industrial Analyzers and Other segment includes advanced gas analysis and monitoring instrumentation used in applications such as oil and gas exploration, beverage and specialty gas analysis, industrial hygiene and safety, food safety and environmental air monitoring.
	The accounting policies of the reportable segments are the same as those described in Note 1 to the Consolidated Financial Statements found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012.  There were no intersegment sales for the three and nine-month periods ended September 30, 2013 and 2012.
	Financial information by reportable segment for the three and nine-month periods ended September 30, 2013 and 2012 is as follows:
		Three months ended					Three months ended
		September 30, 2013					September 30, 2012
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income (Loss)					Income (Loss)
	Permeation	$	5,596,470	$	1,325,605		$	4,680,997	$	1,089,981
	Package Testing	6,328,402		674,797			5,533,628		(638,286		)
	Industrial Analyzers and Other	2,265,001		(85,434		)	2,091,526		313,787
	Total	$	14,189,873	$	1,914,968		$	12,306,151	$	765,482
		Nine months ended					Nine months ended
		September 30, 2013					September 30, 2012
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income					Income (Loss)
	Permeation	$	15,550,031	$	2,630,193		$	15,753,250	$	3,491,806
	Package Testing	18,976,020		1,183,960			12,745,486		(1,923,758		)
	Industrial Analyzers and Other	7,799,015		265,383			6,190,149		196,087
	Total	$	42,325,066	$	4,079,536		$	34,688,885	$	1,764,135

Condensed_Consolidated_Financi1

Condensed Consolidated Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2013
Condensed Consolidated Financial Statements	'
Principles of Consolidation	'
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of MOCON, Inc. and its wholly-owned subsidiaries (collectively the Company).  All intercompany balances and transactions have been eliminated in consolidation.
Recently Adopted Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income
	On January 1, 2013, the Company adopted the FASB issued disclosure requirements with respect to changes in accumulated other comprehensive income (AOCI). Under this new guidance, companies are required to disclose the amount of income (or loss) reclassified out of AOCI to each respective line item on the statements of income where net income is presented on either the face of the financial statements or within the footnotes. The provisions of the guidance are to be applied prospectively for reporting periods beginning after December 15, 2012. The Company has elected to disclose the reclassification in the notes to the financial statements (see Note 7).

Business_Acquisition_Tables

Business Acquisition (Tables)	9 Months Ended
	Sep. 30, 2013
Business Acquisition	'
Schedule of Pro forma financial result and US GAAP conversion adjustments	'
		Net Sales			Net Income		Basic
							Earnings
							per Share
	Supplemental pro forma combined results of operations:
	Nine-month period ended September 30, 2012	$	43,748,390		$	1,185,140	$	0.22
		Nine Months
		Ended
		September 30,
		2012
	Amortization of intangibles	$	278,338
	Interest expense	106,237
	Income tax effect of adjustments	(115,373		)
		$	269,202

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventories	'
Schedule of inventories	'
		September 30,		December 31,
		2013		2012
	Finished products	$	1,460,625	$	1,554,203
	Work-in-process	1,840,414		1,599,761
	Raw materials	3,701,199		3,191,018
		$	7,002,238	$	6,344,982

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2013
Net Income Per Common Share	'
Schedule of reconciliation of the denominators used in the computation of net income per common share - basic, and net income per common share - diluted	'
		Three Months Ended		Nine Months Ended
		September 30,		September 30,
		2013	2012	2013	2012
	Weighted shares of common stock outstanding — basic	5,548,201	5,477,928	5,535,687	5,467,450
	Dilutive impact of share-based awards	136,314	205,508	138,007	227,855
	Weighted shares of common stock outstanding — diluted	5,684,515	5,683,436	5,673,694	5,695,305

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets	'
Schedule of changes in the carrying amount of goodwill	'
		Package					Industrial
		Testing		Permeation			Analyzers & Other		Total
	Balance as of December 31, 2012	$	5,940,437	$	2,179,071		$	609,930	$	8,729,438
	Foreign currency translation	128,963		43,343			—		172,306
	Balance as of September 30, 2013	$	6,069,400	$	2,222,414		$	609,930	$	8,901,744
Schedule of other intangible assets	'
		As of September 30, 2013
		Cost		Accumulated			Net		Estimated
				Amortization					Useful Lives
	Patents	$	1,525,371	$	(373,292	)	$	1,152,079	10 to 17 years
	Trademarks and trade names	4,388,035		(771,765		)	3,616,270		5 to 20 years
	Developed technology	7,596,470		(1,266,078		)	6,330,392		9 years
	Customer relationships	888,370		(148,062		)	740,308		9 years
	Other intangibles	782,718		(25,253		)	757,465		7 years
		$	15,180,964	$	(2,584,450	)	$	12,596,514
		As of December 31, 2012
		Cost		Accumulated			Net		Estimated
				Amortization					Useful Lives
	Patents	$	1,485,164	$	(428,409	)	$	1,056,755	10 to 17 years
	Trademarks and trade names	4,295,181		(608,861		)	3,686,320		5 to 20 years
	Developed technology	7,424,680		(618,723		)	6,805,957		9 years
	Customer relationships	868,280		(72,357		)	795,923		9 years
	Other intangibles	125,118		(88,459		)	36,659		3.75 years
		$	14,198,423	$	(1,816,809	)	$	12,381,614
Schedule of estimated amortization expense related to the intangible assets	'
		Estimated
		Expense
	2013	$	347,616
	2014	1,258,089
	2015	1,253,436
	2016	1,236,837
	2017	1,204,513
	2018 and thereafter	6,102,284

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2013
Marketable Securities	'
Schedule of amortized cost and fair value for held-to-maturity securities by major security type	'
		September 30, 2013
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding		Holding
				Gains		Losses
	Certificates of deposit	$	245,000	$	118	$	—		$	245,118
	Municipal bonds	206,357		1,053		—			207,410
		$	451,357	$	1,171	$	—		$	452,528
		December 31, 2012
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding		Holding
				Gains		Losses
	Certificates of deposit	$	2,802,993	$	8,684	$	—		$	2,811,677
	Municipal bonds	2,903,003		5,057		(30		)	2,908,030
		$	5,705,996	$	13,741	$	(30	)	$	5,719,707

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss)	'
Schedule of adjustments to accumulated other comprehensive income (loss)	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Beginning balance	$	(1,033,751	)	$	(1,992,952	)	$	(627,294	)	$	(590,031	)
	Foreign currency translation adjustments	1,058,066			675,427			651,609			(727,494		)
	Amounts reclassified to earnings	—			—			—			—
	Accumulated other comprehensive income (loss)	$	24,315		$	(1,317,525	)	$	24,315		$	(1,317,525	)

Warranty_Tables

Warranty (Tables)	9 Months Ended
	Sep. 30, 2013
Warranty	'
Schedule of warranty provisions and claims	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Beginning balance	$	240,550		$	250,910		$	240,621		$	205,506
	Acquired provision — Dansensor acquisition	—			—			—			85,413
	Warranty provisions	134,327			135,779			300,827			292,657
	Warranty claims	(133,559		)	(128,749		)	(300,130		)	(325,636		)
	Ending balance	$	241,318		$	257,940		$	241,318		$	257,940

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2013
Debt	'
Schedule of long-term notes payable	'
		September 30,		December 31,
		2013		2012
	Note payable to bank, with interest at 3.46%, payable in monthly principal installments of $72,917 plus interest through March 28, 2016, collateralized by all the assets of the Company except the Dansensor stock.	$	2,260,411	$	2,916,664
	Seller financed note payable (Seller Note), with interest at 3.46%, payable in semi-annual payments of principal and interest totaling $891,000 beginning October 2, 2012 through April 2, 2015, collateralized by 65% of the outstanding stock of Dansensor.	2,747,445		3,517,067
	Capital leases	50,550		59,286
	Total long-term notes payable	$	5,058,406	$	6,493,017
	Less current portion of long-term notes payable	2,624,889		2,566,154
	Total long-term notes payable	$	2,433,517	$	3,926,863
Schedule of future minimum principal payments of the long term notes payable	'
	2013	$	1,087,860
	2014	2,666,060
	2015	995,453
	2016	306,119
	2017	2,914
	Total	$	5,058,406

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation	'
Schedule of amounts recognized in the consolidated financial statements related to stock-based compensation	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Total cost of stock-based compensation	$	129,594		$	116,595		$	390,269		$	350,978
	Amount of income tax benefit recognized in earnings	(14,590		)	(16,897		)	(58,393		)	(62,820		)
	Amount charged against net income	$	115,004		$	99,698		$	331,876		$	288,158
Summary of the option activity	'
		Number of		Weighted			Weighted		Aggregate
		Shares		Average			Average		Intrinsic
				Exercise			Remaining		Value
				Price per			Contractual
				Share			Term
	Outstanding at December 31, 2012	838,662		$	11.84		3.9		$	2,346,063
	Options granted	10,000		14.16			0.3
	Options cancelled/expired	(12,075	)	14.36
	Options exercised	(49,112	)	10.32
	Outstanding at September 30, 2013	787,475		11.93			3.3		$	1,754,035
	Exercisable at September 30, 2013	626,950		11.32			2.7		$	1,696,384
Summary of the status of our unvested option shares	'
		Number of		Weighted
		Shares		Average
				Grant Date
				Fair Value
	Unvested at December 31, 2012	209,925		$	4.04
	Options granted	10,000		$	4.45
	Options cancelled	(11,025	)	$	3.83
	Options vested	(48,375	)	$	4.45
	Unvested at September 30, 2013	160,525		$	3.96

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements	'
Summary of information on assets measured at fair value on a recurring basis	'
				Fair Value
				Measurements
				at the end of
				the Reporting
				Period Using
	Assets:	Carrying		Significant Other
		value		Observable
				Inputs
				(Level 2)
	September 30, 2013:
	Foreign currency contract	$	217,411	$	217,411
	December 31, 2012:
	Foreign currency contract	$	209,370	$	209,370

Business_Segments_Tables

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Business Segments	'
Schedule of financial information by reportable segment	'
		Three months ended					Three months ended
		September 30, 2013					September 30, 2012
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income (Loss)					Income (Loss)
	Permeation	$	5,596,470	$	1,325,605		$	4,680,997	$	1,089,981
	Package Testing	6,328,402		674,797			5,533,628		(638,286		)
	Industrial Analyzers and Other	2,265,001		(85,434		)	2,091,526		313,787
	Total	$	14,189,873	$	1,914,968		$	12,306,151	$	765,482
		Nine months ended					Nine months ended
		September 30, 2013					September 30, 2012
		Trade		Segment			Trade		Segment
		Revenue		Operating			Revenue		Operating
				Income					Income (Loss)
	Permeation	$	15,550,031	$	2,630,193		$	15,753,250	$	3,491,806
	Package Testing	18,976,020		1,183,960			12,745,486		(1,923,758		)
	Industrial Analyzers and Other	7,799,015		265,383			6,190,149		196,087
	Total	$	42,325,066	$	4,079,536		$	34,688,885	$	1,764,135

Condensed_Consolidated_Financi2

Condensed Consolidated Financial Statements (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
	segment	segment
Condensed Consolidated Financial Statements	'	'
Number of reportable segments	3	1

Business_Acquisition_Details

Business Acquisition (Details) (Dansensor, USD $)	9 Months Ended
	Sep. 30, 2012	Apr. 02, 2012
Dansensor	'	'
Business Acquisition	'	'
Cash paid at closing	'	$13,600,000
Allocation of purchase price:	'	'
Purchase price net of cash acquired	'	19,200,000
Supplemental pro-forma combined results of operations:	'	'
Net Sales	43,748,390	'
Net Income	1,185,140	'
Basic Earnings per Share (in dollars per share)	$0.22	'
Acquisition related costs	$790,000	'

Business_Acquisition_Details_2

Business Acquisition (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2012
Adjustments to the supplemental pro forma combined results of operations	'
Adjustments to supplemental pro forma combined results	$269,202
Amortization of intangibles	'
Adjustments to the supplemental pro forma combined results of operations	'
Adjustments to supplemental pro forma combined results	278,338
Interest expense	'
Adjustments to the supplemental pro forma combined results of operations	'
Adjustments to supplemental pro forma combined results	106,237
Income tax effect of adjustments	'
Adjustments to the supplemental pro forma combined results of operations	'
Adjustments to supplemental pro forma combined results	($115,373)

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventories	'	'
Finished products	$1,460,625	$1,554,203
Work-in-process	1,840,414	1,599,761
Raw materials	3,701,199	3,191,018
Total	$7,002,238	$6,344,982

Net_Income_Per_Common_Share_De

Net Income Per Common Share (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net Income Per Common Share	'	'	'	'
Weighted shares of common stock outstanding - basic	5,548,201	5,477,928	5,535,687	5,467,450
Dilutive impact of share-based awards	136,314	205,508	138,007	227,855
Weighted shares of common stock outstanding - diluted	5,684,515	5,683,436	5,673,694	5,695,305
Number of outstanding stock options excluded from the net income per common share calculation	255,650	126,700	255,650	126,700

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
		Package Testing	Permeation	Industrial Analyzers and Other	Industrial Analyzers and Other
Changes in the carrying amount of goodwill	'	'	'	'	'
Balance at the beginning of the period	$8,729,438	$5,940,437	$2,179,071	$609,930	$609,930
Foreign currency translation	172,306	128,963	43,343	'	'
Balance at the end of the period	$8,901,744	$6,069,400	$2,222,414	$609,930	$609,930

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 2) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Patents

Patents

Patents

Patents

Patents

Patents

Trademarks and trade names

Trademarks and trade names

Trademarks and trade names

Trademarks and trade names

Trademarks and trade names

Trademarks and trade names

Developed technology

Developed technology

Customer relationships

Customer relationships

Other intangibles

Other intangibles

Minimum

Minimum

Maximum

Maximum

Minimum

Minimum

Maximum

Maximum

Other Intangible Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost

$15,180,964

'

$15,180,964

'

$14,198,423

$1,525,371

$1,485,164

'

'

'

'

$4,388,035

$4,295,181

'

'

'

'

$7,596,470

$7,424,680

$888,370

$868,280

$782,718

$125,118

Accumulated Amortization

-2,584,450

'

-2,584,450

'

-1,816,809

-373,292

-428,409

'

'

'

'

-771,765

-608,861

'

'

'

'

-1,266,078

-618,723

-148,062

-72,357

-25,253

-88,459

Net

12,596,514

'

12,596,514

'

12,381,614

1,152,079

1,056,755

'

'

'

'

3,616,270

3,686,320

'

'

'

'

6,330,392

6,805,957

740,308

795,923

757,465

36,659

Estimated Useful Lives

'

'

'

'

'

'

'

'10 years

'10 years

'17 years

'17 years

'

'

'5 years

'5 years

'20 years

'20 years

'9 years

'9 years

'9 years

'9 years

'7 years

'3 years 9 months

Total amortization expense

307,176

291,375

889,480

604,025

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization expense related to the intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2013

347,616

'

347,616

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

1,258,089

'

1,258,089

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

1,253,436

'

1,253,436

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

1,236,837

'

1,236,837

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

1,204,513

'

1,204,513

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018 and thereafter

$6,102,284

'

$6,102,284

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Marketable Securities	'	'	'	'	'
Other than temporary impairment	'	'	$0	$0	'
Maturity period of marketable securities	'	'	'3 months	'	'
Gross realized gains or losses	0	0	0	0	'
Amortized cost	451,357	'	451,357	'	5,705,996
Gross Unrealized Holding Gains	1,171	'	1,171	'	13,741
Gross Unrealized Holding Losses	'	'	'	'	-30
Fair Value	452,528	'	452,528	'	5,719,707
Certificates of deposit	'	'	'	'	'
Marketable Securities	'	'	'	'	'
Amortized cost	245,000	'	245,000	'	2,802,993
Gross Unrealized Holding Gains	118	'	118	'	8,684
Fair Value	245,118	'	245,118	'	2,811,677
Municipal bonds	'	'	'	'	'
Marketable Securities	'	'	'	'	'
Amortized cost	206,357	'	206,357	'	2,903,003
Gross Unrealized Holding Gains	1,053	'	1,053	'	5,057
Gross Unrealized Holding Losses	'	'	'	'	-30
Fair Value	$207,410	'	$207,410	'	$2,908,030

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss)	'	'	'	'
Beginning balance	($1,033,751)	($1,317,525)	($627,294)	($590,031)
Foreign currency translation adjustments	1,058,066	675,427	651,609	-727,494
Accumulated other comprehensive income (loss)	$24,315	($1,317,525)	$24,315	($1,317,525)

Investment_in_Affiliated_Compa1

Investment in Affiliated Company (Details) (Luxcel)	3 Months Ended
	Sep. 30, 2013	Jan. 31, 2010	Jan. 31, 2010
	USD ($)	USD ($)	EUR (€)
	item
Investment in Affiliated Company	'	'	'
Cost method investment	'	$3,600,000	€ 2,500,000
Cost ownership interest (as a percent)	'	16.90%	16.90%
Payment under the license and distribution agreement	200,000	'	'
Number of licenses acquired	2	'	'
Term of licenses acquired	'4 years	'	'
Total commitments for work orders including amount already paid	300,000	'	'
Payment for research & development work order	$100,000	'	'

Warranty_Details

Warranty (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Warranty	'	'	'	'
Period of warranties, low end of the range	'	'	'90 days	'90 days
Period of warranties, high end of the range	'	'	'1 year	'1 year
Warranty provisions and claims for the years	'	'	'	'
Beginning balance	$240,550	$250,910	$240,621	$205,506
Acquired provision - Dansensor acquisition	'	'	'	85,413
Warranty provisions	134,327	135,779	300,827	292,657
Warranty claims	-133,559	-128,749	-300,130	-325,636
Ending balance	$241,318	$257,940	$241,318	$257,940

Debt_Details

Debt (Details)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
	USD ($)	USD ($)	Dansensor	Dansensor	Dansensor	Secured term note payable	Revolving line of credit	Revolving line of credit	Seller financed secured note payable	Bank term note payable and seller financed secured note payable
			USD ($)	DKK	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Bank Financing	'	'	'	'	'	'	'	'	'	'
Note payable to the bank, with interest at 3.46%, payable in monthly principal installments of $72,917 plus interest through March 28, 2016, collateralized by all the assets of the Company except Dansensor stock	$2,260,411	$2,916,664	'	'	'	'	'	'	'	'
Seller financed note payable (Seller Note), with interest at 3.46%, payable in semi-annual payments of principal and interest totaling $891,000 beginning October 2, 2012 through April 2, 2015, collateralized by 65% of the outstanding stock of Dansensor.	2,747,445	3,517,067	'	'	'	'	'	'	'	'
Capital leases	50,550	59,286	'	'	'	'	'	'	'	'
Total long-term notes payable	5,058,406	6,493,017	'	'	'	'	'	'	'	'
Less current portion of long-term notes payable	2,624,889	2,566,154	'	'	'	'	'	'	'	'
Total long-term notes payable	2,433,517	3,926,863	'	'	'	'	'	'	'	'
Fixed interest rate (as a percent)	'	'	'	'	'	3.46%	'	'	3.46%	'
Monthly principal installments	'	'	'	'	'	72,917	'	'	'	'
Semi-annual installments payable of principal and interest	'	'	'	'	'	'	'	'	891,000	'
Percentage of common stock secured for debt	'	'	'	'	'	'	'	'	65.00%	'
Maximum borrowing capacity	'	'	1,700,000	10,000,000	'	'	5,000,000	5,000,000	'	'
Reference rate	'	'	'	'	'	'	'one-month LIBOR	'one-month LIBOR	'	'
Basis spread over reference rate (as a percent)	'	'	'	'	'	'	0.02%	0.02%	'	'
Interest rate at the end of period (as a percent)	'	'	'	'	'	'	2.00%	2.00%	'	'
Outstanding revolving line of credit	'	'	0	'	652,000	'	2,550,000	4,675,000	'	'
Interest rate charged on borrowings (as a percent)	'	'	4.35%	4.35%	'	'	'	'	'	'
Future minimum principal payments of the long- term notes payable	'	'	'	'	'	'	'	'	'	'
2013	'	'	'	'	'	'	'	'	'	1,087,860
2014	'	'	'	'	'	'	'	'	'	2,666,060
2015	'	'	'	'	'	'	'	'	'	995,453
2016	'	'	'	'	'	'	'	'	'	306,119
2017	'	'	'	'	'	'	'	'	'	2,914
Total long-term notes payable	'	'	'	'	'	'	'	'	'	$5,058,406

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Income Taxes	'	'	'	'	'
Provision for income tax expense (as a percent)	25.00%	33.00%	20.00%	38.00%	'
Liability for gross unrecognized tax benefits	$297,000	'	$297,000	'	$265,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
			Q
Stock-Based Compensation	'	'	'	'	'
Total cost of stock-based compensation	$129,594	$116,595	$390,269	$350,978	'
Amount of income tax benefit recognized in earnings	-14,590	-16,897	-58,393	-62,820	'
Amount charged against net income	115,004	99,698	331,876	288,158	'
Options	'	'	'	'	'
Assumptions used for estimating fair value of options using Black-Scholes option pricing model	'	'	'	'	'
Expected contractual term	'	'	'7 years	'	'
Number of prior quarters used in calculation of dividend yield	'	'	4	'	'
Number of Shares	'	'	'	'	'
Outstanding at the beginning of the period (in shares)	'	'	838,662	'	'
Options granted (in shares)	'	'	10,000	'	'
Options cancelled/expired (in shares)	'	'	-12,075	'	'
Options exercised (in shares)	'	'	-49,112	'	'
Outstanding at the end of the period (in shares)	787,475	'	787,475	'	838,662
Exercisable at the end of the period (in shares)	626,950	'	626,950	'	'
Weighted Average Exercise Price per Share	'	'	'	'	'
Outstanding at the beginning of the period (in dollars per share)	'	'	$11.84	'	'
Options granted (in dollars per share)	'	'	$14.16	'	'
Options cancelled/expired (in dollars per share)	'	'	$14.36	'	'
Options exercised (in dollars per share)	'	'	$10.32	'	'
Outstanding at the end of the period (in dollars per share)	$11.93	'	$11.93	'	$11.84
Exercisable at the end of the period (in dollars per share)	$11.32	'	$11.32	'	'
Weighted Average Remaining Contractual Term	'	'	'	'	'
Outstanding at the end of the period	'	'	'3 years 3 months 18 days	'	'3 years 10 months 24 days
Options granted	'	'	'3 months 18 days	'	'
Exercisable at the end of the period	'	'	'2 years 8 months 12 days	'	'
Aggregate Intrinsic Value	'	'	'	'	'
Outstanding at the end of the period (in dollars)	1,754,035	'	1,754,035	'	2,346,063
Exercisable at the end of the period (in dollars)	1,696,384	'	1,696,384	'	'
Total intrinsic value of options exercised (in dollars)	$10,133	$44,382	$183,421	$336,759	'
2006 stock incentive plan	'	'	'	'	'
Stock-Based Compensation	'	'	'	'	'
Number of shares of common stock for options and other stock-based incentive awards that are still available for grant	273,477	'	273,477	'	'
2006 stock incentive plan and 1998 stock option plan	'	'	'	'	'
Stock-Based Compensation	'	'	'	'	'
Number of shares of common stock for options and other stock-based incentive awards that are still available for grant	787,475	'	787,475	'	'

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Additional disclosure	'	'	'	'
Total unrecognized compensation cost related to unvested stock-based compensation granted (in dollars)	$459,965	'	$459,965	'
Weighted-average period over which unrecognized compensation expense is expected to be recognized	'	'	'1 year 2 months 12 days	'
Options	'	'	'	'
Unvested options, Number of Shares	'	'	'	'
Unvested at the beginning of the period (in shares)	'	'	209,925	'
Options granted (in shares)	'	'	10,000	'
Options cancelled (in shares)	'	'	-11,025	'
Options vested (in shares)	'	'	-48,375	'
Unvested at the end of the period (in shares)	160,525	'	160,525	'
Unvested options, Weighted Average Grant Date Value	'	'	'	'
Unvested at the beginning of the period (in dollars per share)	'	'	$4.04	'
Options granted (in dollars per share)	'	'	$4.45	'
Options cancelled (in dollars per share)	'	'	$3.83	'
Options vested (in dollars per share)	'	'	$4.45	'
Unvested at the end of the period (in dollars per share)	$3.96	'	$3.96	'
Additional disclosure	'	'	'	'
Fair value of option shares vested	$71,756	$65,697	$215,269	$197,042

Derivative_Instrument_Details

Derivative Instrument (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
	USD ($)	USD ($)	DKK	USD ($)
	item	item
Derivative Instrument	'	'	'	'
Number of foreign currency contracts	1	1	'	'
Notional amount of foreign currency contract	$2,800,000	$2,800,000	15,700,000	'
Fair value of foreign currency contract resulted in an asset	217,400	217,400	'	209,000
Increase in the fair value of contract recognized in other income (expense)	$103,100	$8,000	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair value measurements	'	'
Foreign currency contract	$217,400	$209,000
Recurring basis | Significant Other Observable Inputs (Level 2)	'	'
Fair value measurements	'	'
Foreign currency contract	217,411	209,370
Recurring basis | Carrying value	'	'
Fair value measurements	'	'
Foreign currency contract	$217,411	$209,370

Business_Segments_Details

Business Segments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
		segment	segment	segment
Business Segments	'	'	'	'
Number of Operating Segments	'	3	4	'
Number of reportable segments	'	'	3	1
Financial information by reportable segment	'	'	'	'
Trade Revenue	$14,189,873	$12,306,151	$42,325,066	$34,688,885
Segment Operating Income	1,914,968	765,482	4,079,536	1,764,135
Permeation	'	'	'	'
Financial information by reportable segment	'	'	'	'
Trade Revenue	5,596,470	4,680,997	15,550,031	15,753,250
Segment Operating Income	1,325,605	1,089,981	2,630,193	3,491,806
Package Testing	'	'	'	'
Financial information by reportable segment	'	'	'	'
Trade Revenue	6,328,402	5,533,628	18,976,020	12,745,486
Segment Operating Income	674,797	-638,286	1,183,960	-1,923,758
Industrial Analyzers and Other	'	'	'	'
Financial information by reportable segment	'	'	'	'
Trade Revenue	2,265,001	2,091,526	7,799,015	6,190,149
Segment Operating Income	-85,434	313,787	265,383	196,087
Intersegment	'	'	'	'
Financial information by reportable segment	'	'	'	'
Trade Revenue	$0	$0	$0	$0